RhumbLine Advisers
FENC icon

RhumbLine Advisers’s Fennec Pharmaceuticals FENC Stock Holding History

RhumbLine Advisers’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$192K Buy
31,298
+2,260
+8% +$17.4K ﹤0.01% 3138
2025
Q4 		$224K Sell
29,038
-4,484
-13% -$36.8K ﹤0.01% 3128
2025
Q3 		$314K Sell
33,522
-375
-1% -$3.25K ﹤0.01% 2968
2025
Q2 		$281K Buy
33,897
+533
+2% +$3.65K ﹤0.01% 3027
2025
Q1 		$203K Sell
33,364
-935
-3% -$6K ﹤0.01% 3096
2024
Q4 		$217K Buy
34,299
+3,911
+13% +$20K ﹤0.01% 3150
2024
Q3 		$152K Buy
30,388
+1,278
+4% +$7.39K ﹤0.01% 3361
2024
Q2 		$178K Buy
29,110
+8,987
+45% +$74.6K ﹤0.01% 3290
2024
Q1 		$224K Buy
20,123
+240
+1% +$2.41K ﹤0.01% 3114
2023
Q4 		$223K Sell
19,883
-664
-3% -$5.5K ﹤0.01% 3127
2023
Q3 		$154K Buy
20,547
+816
+4% +$6.64K ﹤0.01% 3291
2023
Q2 		$174K Buy
+19,731
New +$164K ﹤0.01% 3308
2021
Q2 		– Sell
-19,802
Closed -$123K – 3030
2021
Q1 		$123K Sell
19,802
-220
-1% -$1.66K ﹤0.01% 2912
2020
Q4 		$149K Buy
20,022
+1,600
+9% +$12.2K ﹤0.01% 2903
2020
Q3 		$112K Sell
18,422
-506
-3% -$3.57K ﹤0.01% 2845
2020
Q2 		$158K Buy
+18,928
New +$141K ﹤0.01% 2850
2019
Q2 		– Sell
-13,375
Closed -$65K – 2981
2019
Q1 		$65K Sell
13,375
-280
-2% -$1.84K ﹤0.01% 2903
2018
Q4 		$87K Buy
+13,655
New +$95.4K ﹤0.01% 2899

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

RhumbLine Advisers's FENC Position: Q1 2026 in Review

RhumbLine Advisers increased its Fennec Pharmaceuticals (FENC) stake by 7.8% in Q1 2026, buying an estimated $17.4K and bringing the position to 31,298 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #3138.

RhumbLine Advisers first reported a position in FENC in Q4 2018 and has held it in 18 quarters since. The position peaked at $314K in Q3 2025. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • RhumbLine Advisers held 31,298 shares of Fennec Pharmaceuticals worth $192K as of Q1 2026.
  • RhumbLine Advisers bought 2,260 Fennec Pharmaceuticals shares in Q1 2026, an estimated $17.4K.
  • Fennec Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3138 holding.
  • RhumbLine Advisers first reported a position in Fennec Pharmaceuticals in Q4 2018 and has held it in 18 quarters since.
  • RhumbLine Advisers's Fennec Pharmaceuticals position peaked at $314K in Q3 2025.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.